Bone marrow transplantation for chronic lymphocytic leukemia

Research output: Contribution to journalArticle

Abstract

The use of bone marrow transplant (BMT) for patients with chronic lymphocytic leukemia (CLL) is a relatively new approach when compared to the use of this therapy for other hematologic malignancies. The long natural history of CLL and significant procedure-related mortality initially deterred the use of BMT for CLL. However, improvement in transplantation procedures and supportive care paved the way for the use of BMT in patients with CLL. There are now multiple reports showing complete remissions with both autologous and allogeneic BMT. The follow-up remains short, therefore, the durability of these remissions remains to be determined. Several innovative approaches to BMT for CLL are now being explored and include non- myeloablative preparative regimens for allogeneic transplants, purging autologous grafts, and induction of graft-versus-leukemia effects. Ultimately, however, long-term disease-free and overall survival will need to be shown before BMT for CLL will gain widespread acceptance.

Original languageEnglish (US)
Pages (from-to)60-64
Number of pages5
JournalSeminars in Oncology
Volume25
Issue number1
StatePublished - 1998

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Bone Marrow Transplantation
Transplants
Bone Marrow
Autografts
Hematologic Neoplasms
Disease-Free Survival
Leukemia
Transplantation
Mortality

ASJC Scopus subject areas

  • Oncology

Cite this

Bone marrow transplantation for chronic lymphocytic leukemia. / Flinn, I. W.; Vogelsang, Georgia Boyce.

In: Seminars in Oncology, Vol. 25, No. 1, 1998, p. 60-64.

Research output: Contribution to journalArticle

@article{5d9f218138d94991a6c7430024086ebd,
title = "Bone marrow transplantation for chronic lymphocytic leukemia",
abstract = "The use of bone marrow transplant (BMT) for patients with chronic lymphocytic leukemia (CLL) is a relatively new approach when compared to the use of this therapy for other hematologic malignancies. The long natural history of CLL and significant procedure-related mortality initially deterred the use of BMT for CLL. However, improvement in transplantation procedures and supportive care paved the way for the use of BMT in patients with CLL. There are now multiple reports showing complete remissions with both autologous and allogeneic BMT. The follow-up remains short, therefore, the durability of these remissions remains to be determined. Several innovative approaches to BMT for CLL are now being explored and include non- myeloablative preparative regimens for allogeneic transplants, purging autologous grafts, and induction of graft-versus-leukemia effects. Ultimately, however, long-term disease-free and overall survival will need to be shown before BMT for CLL will gain widespread acceptance.",
author = "Flinn, {I. W.} and Vogelsang, {Georgia Boyce}",
year = "1998",
language = "English (US)",
volume = "25",
pages = "60--64",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Bone marrow transplantation for chronic lymphocytic leukemia

AU - Flinn, I. W.

AU - Vogelsang, Georgia Boyce

PY - 1998

Y1 - 1998

N2 - The use of bone marrow transplant (BMT) for patients with chronic lymphocytic leukemia (CLL) is a relatively new approach when compared to the use of this therapy for other hematologic malignancies. The long natural history of CLL and significant procedure-related mortality initially deterred the use of BMT for CLL. However, improvement in transplantation procedures and supportive care paved the way for the use of BMT in patients with CLL. There are now multiple reports showing complete remissions with both autologous and allogeneic BMT. The follow-up remains short, therefore, the durability of these remissions remains to be determined. Several innovative approaches to BMT for CLL are now being explored and include non- myeloablative preparative regimens for allogeneic transplants, purging autologous grafts, and induction of graft-versus-leukemia effects. Ultimately, however, long-term disease-free and overall survival will need to be shown before BMT for CLL will gain widespread acceptance.

AB - The use of bone marrow transplant (BMT) for patients with chronic lymphocytic leukemia (CLL) is a relatively new approach when compared to the use of this therapy for other hematologic malignancies. The long natural history of CLL and significant procedure-related mortality initially deterred the use of BMT for CLL. However, improvement in transplantation procedures and supportive care paved the way for the use of BMT in patients with CLL. There are now multiple reports showing complete remissions with both autologous and allogeneic BMT. The follow-up remains short, therefore, the durability of these remissions remains to be determined. Several innovative approaches to BMT for CLL are now being explored and include non- myeloablative preparative regimens for allogeneic transplants, purging autologous grafts, and induction of graft-versus-leukemia effects. Ultimately, however, long-term disease-free and overall survival will need to be shown before BMT for CLL will gain widespread acceptance.

UR - http://www.scopus.com/inward/record.url?scp=0031888492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031888492&partnerID=8YFLogxK

M3 - Article

C2 - 9482527

AN - SCOPUS:0031888492

VL - 25

SP - 60

EP - 64

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1

ER -